NOTCH mutation	Adenoid Cystic Carcinoma	NOTCH mutation	Adenoid Cystic Carcinoma	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3	AL101 Sensitive: C3 – Early Trials AL101 Sensitive : C3
NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma	NOTCH1 positive + FGFR2 mutation	Adenoid Cystic Carcinoma	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive : C4	lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive: C4 – Case Studies lenvatinib + erdafitinib + γ-secretase inhibitor Sensitive : C4
NOTCH2 mutation	Triple Negative Breast Cancer	NOTCH2 mutation	Triple Negative Breast Cancer	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	gefitinib + nirogacestat Sensitive: D – Preclinical gefitinib + nirogacestat Sensitive : D	gefitinib + nirogacestat Sensitive: D – Preclinical gefitinib + nirogacestat Sensitive : D
NOTCH1 expression	Acute Lymphocytic Leukemia	NOTCH1 expression	Acute Lymphocytic Leukemia	sirolimus + MRK003 Sensitive: D – Preclinical sirolimus + MRK003 Sensitive : D	sirolimus + MRK003 Sensitive: D – Preclinical sirolimus + MRK003 Sensitive : D
NOTCH1 mutation	Mantle Cell Lymphoma	NOTCH1 mutation	Mantle Cell Lymphoma	Compound E Sensitive: D – Preclinical Compound E Sensitive : D	Compound E Sensitive: D – Preclinical Compound E Sensitive : D
NOTCH1 mutation	Triple Negative Breast Cancer	NOTCH1 mutation	Triple Negative Breast Cancer	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D	nirogacestat Sensitive: D – Preclinical nirogacestat Sensitive : D

γ-secretase inhibitor

γ-secretase inhibitor

Associations(7)

Associations
(7)